Summary of Significant Accounting Policies - Schedule of Manufacturing, Development, and Other Contingent Milestone Payments (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Total manufacturing and other commitments	$ 8,432
Active Pharmaceutical Ingredients [Member]
Summary Of Significant Accounting Policies [Line Items]
Achievement of certain milestones related to validation of API and regulatory approval of molgramostim	2,300
Molgradex Nebulizer Manufacturer [Member]
Summary Of Significant Accounting Policies [Line Items]
Achievement of various development activities and regulatory approval of nebulizer utilized to administer molgramostim	$ 6,132